| Pivotal Health And Rehab | |
|
103 Sum Mor Dr, West Columbia, SC 29169-4828 | |
| (803) 254-4699 | |
| (803) 851-1235 |
| Full Name | Pivotal Health And Rehab |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Multi-specialty |
| Location | 103 Sum Mor Dr, West Columbia, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386150613 | NPI | - | NPPES |
| Provider Name | Ryan Bowers |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1679899488 PECOS PAC ID: 6002096658 Enrollment ID: I20110214000842 |
News Archive
A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by cornea swelling that can eventually lead to the need for corneal transplantation.
One of the significant players in this event is the molecule cytokine lymphotoxin-alpha (LTA), which helps to regulate inflammation, a result of the emergency call upon the body's immune system.
On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).
In a study of more than 200 Hispanics with diabetes, researchers at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons found a significant association between depression severity and poor glycemic control (PGC).
› Verified 3 days ago
| Provider Name | John Evans Stavrakos |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1063426724 PECOS PAC ID: 3274563440 Enrollment ID: I20161003000443 |
News Archive
A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by cornea swelling that can eventually lead to the need for corneal transplantation.
One of the significant players in this event is the molecule cytokine lymphotoxin-alpha (LTA), which helps to regulate inflammation, a result of the emergency call upon the body's immune system.
On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).
In a study of more than 200 Hispanics with diabetes, researchers at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons found a significant association between depression severity and poor glycemic control (PGC).
› Verified 3 days ago
| Provider Name | Ashley Torroni Hazelrigg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477017606 PECOS PAC ID: 2769725423 Enrollment ID: I20190521000279 |
News Archive
A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by cornea swelling that can eventually lead to the need for corneal transplantation.
One of the significant players in this event is the molecule cytokine lymphotoxin-alpha (LTA), which helps to regulate inflammation, a result of the emergency call upon the body's immune system.
On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).
In a study of more than 200 Hispanics with diabetes, researchers at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons found a significant association between depression severity and poor glycemic control (PGC).
› Verified 3 days ago
| Provider Name | Angelina Dow |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376137745 PECOS PAC ID: 2961891999 Enrollment ID: I20211113000041 |
News Archive
A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by cornea swelling that can eventually lead to the need for corneal transplantation.
One of the significant players in this event is the molecule cytokine lymphotoxin-alpha (LTA), which helps to regulate inflammation, a result of the emergency call upon the body's immune system.
On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).
In a study of more than 200 Hispanics with diabetes, researchers at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons found a significant association between depression severity and poor glycemic control (PGC).
› Verified 3 days ago
| Provider Name | Hannah Rhea Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285228403 PECOS PAC ID: 0042694416 Enrollment ID: I20220902001130 |
News Archive
A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by cornea swelling that can eventually lead to the need for corneal transplantation.
One of the significant players in this event is the molecule cytokine lymphotoxin-alpha (LTA), which helps to regulate inflammation, a result of the emergency call upon the body's immune system.
On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).
In a study of more than 200 Hispanics with diabetes, researchers at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons found a significant association between depression severity and poor glycemic control (PGC).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pivotal Health And Rehab Po Box 2632, Lexington, SC 29071-2632 Ph: (803) 218-9886 | Pivotal Health And Rehab 103 Sum Mor Dr, West Columbia, SC 29169-4828 Ph: (803) 254-4699 |
News Archive
A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by cornea swelling that can eventually lead to the need for corneal transplantation.
One of the significant players in this event is the molecule cytokine lymphotoxin-alpha (LTA), which helps to regulate inflammation, a result of the emergency call upon the body's immune system.
On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).
In a study of more than 200 Hispanics with diabetes, researchers at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons found a significant association between depression severity and poor glycemic control (PGC).
› Verified 3 days ago